Actualites therapeutiques dans le traitement medical du cancer de la prostate resistant a la castration.

Androstenols/administration & dosage; Antineoplastic Agents, Hormonal/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Phenylthiohydantoin/administration & dosage/analogs & derivatives; Prostatic Neoplasms/drug therapy/mortality/pathology/surgery; Randomized Controlled Trials as Topic; Taxoids/administration & dosage; Treatment Outcome

Abstract :

[en] Docetaxel chemotherapy is a standard treatment for fit men with symptomatic castration-resistant prostate cancer. Unfortunately docetaxel resistant disease will systematically develop and second-line treatment may be appropriate. Until recently no standard treatment was approved in this setting and mitoxantrone was commonly used. Three new drugs have shown benefit in randomised phase 3 multicenter clinical trials published since 2010. Cabazitaxel, abiraterone and enzalutamide were shown to prolong overall survival of men with metastatic castration-resistant prostate cancer previously treated with chemotherapy. Although still modest these results were deemed clinically significant and led to the reimbursement of Jevtana (cabazitaxel) and Zytiga (abiraterone) in Belgium in 2012.

Disciplines :

Oncology

Author, co-author :

Sautois, Brieuc ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

GENNIGENS, Christine ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Language :

French

Title :

Actualites therapeutiques dans le traitement medical du cancer de la prostate resistant a la castration.

Alternative titles :

[en] New treatments for castration-resistant prostate cancer

Publication date :

2013

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

94-6

Peer reviewed :

Peer reviewed

Available on ORBi :

since 09 September 2013

Statistics

Number of views

239 (8 by ULiège)

Number of downloads

768 (8 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Tannock IF, de Wit R, Berry WR, et al. - Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004, 351, 1502-1512.
Tannock IF, Osoba D, Stockler MR et al.- Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer : a Canadian randomized trial with palliative end points. J Clin Oncol, 1996, 14, 1756-1764.
de Bono JS, Oudard S, Ozguroglu M, et al. - Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet, 2010, 376, 1147-1154.
de Bono JS, Logothetis CJ, Molina A, et al. - Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 2011, 364, 1995-2005.
Scher HI, Fizazi K, Saad F, et al. - Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 2012, 367, 1187-1197.
Kantoff PW, Higano CS, Shore ND, et al. - Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010, 363, 411-422.
Parker C, Heinrich D, O'Sullivan JM, et al. - Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC) : a phase III randomized trial (ALSYMPCA). [abstract]. Eur J Cancer, 2011, 47, (Abstr 1 LBA).
Fizazi K, Carducci M, Smith M, et al. - Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet, 2011, 377, 813-822.